Health Affairs, 24, no. 4 (2005): 1032-1038 doi: 10.1377/hlthaff.24.4.1032 © 2005 by Project HOPE	New Online   How Would Obama, McCain Cover The Uninsured?   Debating Cost Of Uninsured   Try Medicare-For-All   HA Blog Top 10

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Morden, N. E. Articles by Sullivan, S. D. Search for Related Content PubMed PubMed Citation Articles by Morden, N. E. Articles by Sullivan, S. D. Related Collections Access To Care Business Of Health Consumer Issues Health Reform Managed Care - Medicaid Managed Care - Medicare Medicaid Medicare Pharmaceuticals State/Local Issues Health Spending

Health Tracking

MARKETWATCH

States’ Control Of Prescription Drug Spending: A Heterogeneous Approach

In an effort to balance Medicaid budgets, states use prescription drug cost containment tools in unique ways and in varying combinations. We report on the variability in state-level strategies to control the cost of prescription drugs and describe broad state-to-state differences in per beneficiary spending on drugs. This heterogeneity raises the question of appropriate state program variability. Research is needed to determine the medically, ethically, and legally most suitable means of controlling drug costs, especially as the Medicare Part D drug plan will likely recapitulate the prescription drug program variability observed among the states.

                      What's this?

This article has been cited by other articles:

				A. R. Rahimi, J. A. Spertus, K. J. Reid, S. M. Bernheim, and H. M. Krumholz Financial Barriers to Health Care and Outcomes After Acute Myocardial Infarction JAMA, March 14, 2007; 297(10): 1063 - 1072. [Abstract] [Full Text] [PDF]

				J. M. Paterson, A. Laupacis, K. Bassett, G. M. Anderson, and for the BC-Ontario Pharmacosurveillance for Decisi Using Pharmacoepidemiology To Inform Drug Coverage Policy: Initial Lessons From A Two-Province Collaborative Health Aff., September 1, 2006; 25(5): 1436 - 1443. [Abstract] [Full Text] [PDF]

				P. J. Neumann Emerging Lessons From The Drug Effectiveness Review Project Health Aff., July 1, 2006; 25(4): W262 - W271. [Abstract] [Full Text] [PDF]